Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.58 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422551 | 0.95 | ESR1 (0.58) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL11186372 | 0.91 | ESR1 (0.61) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL8473947 | 0.90 | ESR1 (0.58) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL11184205 | 0.90 | ESR1 (0.59) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL1359828 | 0.89 | ESR1 (0.56) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL5419421 | 0.87 | ESR1 (0.53) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL1359801 | 0.87 | ESR1 (0.56) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL7107781 | 0.86 | ESR1 (0.60) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL8473855 | 0.86 | ESR1 (0.55) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL8474177 | 0.86 | ESR1 (0.57) | ESR1ESR2GCGRPSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | claimed |
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY | 2005-11-24 | — | — | US | claimed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1551822-B1 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LILLY CO ELI (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY | 2005-11-24 | — | — | US | disclosed |
| EP-1551822-A2 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004009578-A2 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | NR5A1, NR3C2, OXER1 | ESR1 6/4885ESR2 8/4885GCGR 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.